

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449a ATTORNEY'S MARK INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: November 10, 2004 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/777,288
				Filing Date	02/13/2004
				First Named Inventor	Takao ISOGAI
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	1	Attorney Docket Number	084335-0182

[illegible]

Examiner Signature		Date Considered	
-----------------------	---	--------------------	---

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number 10/777,288
Filing Date 02/13/2004
First Named Inventor Takao ISOGL et al.
Group Art Unit 1653
Examiner Name Unassigned
Attorney Docket Number 084335-0182

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
AB	A1	EP	1 195 434	A	Taisho Pharmaceutical Co.	04/10/2002		
AB	A2	WO	02/068652	A	Curagen Corporation	09/06/2002		
AB	A3	WO	2004/016225	A	Genentech, Inc.	02/26/2004		
AB	A4	WO	2004/024760	A	Takeda Chemical Ind. Ltd.	03/25/2004		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
AB	A5	Database EMBL, December 13, 2001, STRAUSBERG et al., "Homo Sapiens Solute Carrier Family 10 (Sodium/Bile Acid Cotransporter Family), Member 4 mRNA (cDNA Clone MGC: 29802 Image 4897519), Complete CDS," XP-002332592.	
	A6	DATABASE EMBL, December 1, 2001, STRAUSBERG et al., "Solute Carrier Family 10 (Sodium/Bile Acid Cotransporter Family), Member 4," XP-002332593.	
	A7	DATABASE EMBL, December 18, 2003, "Sequence 113 From Patent WO 02/068652," XP-002332594.	
	A8	DATABASE EPO PROTEINS, December 18, 2003, "Sequence 114 From Patent WO 02/068652," XP-002332595.	
	A9	DATABASE EMBL, September 9, 2003, YAMAMOTO, "Homo Sapiens cDNA FLJ44578 Fis, Clone 3NB692004045, Weakly Similar to Sodium/bile Acid Cotransporter," XP-002332596.	
	A10	DATABASE GENESEQ, May 20, 2004, "Human Tumour-Associated Antigenic Target (TAT) cDNA Sequence #69," XP-002332597.	
	A11	DATABASE GENESEQ, May 20, 2004, "Human Tumour-Associated Antigenic Target (TAT) Polypeptide #65," XP-002332598.	
	A12	DATABASE GENESEQ, June 17, 2004, "Human TCH162 cDNA, Seq. Id 15," XP-002332599.	
AB	A13	DATABASE GENESEQ, September 16, 2004, "Novel Protein and its DNA," XP-002332600.	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.